<DOC>
	<DOCNO>NCT00635921</DOCNO>
	<brief_summary>Objective : The aim double-blind , placebo-controlled study evaluate efficacy tolerability ziprasidone treatment adult patient Borderline Personality Disorder ( BPD ) . Method : Sixty BPD patient include 12-week , single-center , double-blind , placebo-controlled study . The subject randomly assign ziprasidone placebo 1:1 ratio follow two-week baseline period . The Clinical Global Impression scale use BPD patient ( CGI-BPD ) primary outcome measure , scale self-reports related affect , behavior , psychosis , general psychopathology domains clinical safety include .</brief_summary>
	<brief_title>Ziprasidone Treatment Borderline Personality Disorder</brief_title>
	<detailed_description>The American Psychiatric Association ( APA ) Guidelines Treatment Borderline personality disorder recommend pharmacological treatment BPD important adjunctive role , especially diminution symptom affective instability , impulsivity , psychotic-like symptom , self-destructive behavior . Studies conduct low dos conventional antipsychotic show significant improvement specific symptom hostility , impulsiveness , mood , psychotic symptom . The introduction atypical antipsychotic , favorable tolerance profile , increase clinician ' option treat BPD . Olanzapine proven efficacy four double-blind , placebo-controlled clinical trial patient BPD . Ziprasidone atypical antipsychotic pharmacological action serotonergic , dopaminergic adrenergic receptor . It proven effective schizophrenia , schizoaffective acute mania disorder incidence side effect low . Although clinical finding pharmacological activity ziprasidone suggest drug may therapeutic benefit BPD patient , control study yet conduct patient . We carry randomize , double-blind , placebo-controlled study evaluate efficacy tolerability ziprasidone management BPD patient moderate-high clinical severity .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Borderline Personality Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>DSMIV diagnosis Borderline Personality Disorder Age 18 45 year Clinical Global Impression Severity ( CGIS ) score &gt; 4 No comorbidity schizophrenia , druginduced psychosis , organic brain syndrome , alcohol substance dependence , bipolar disorder , mental retardation , major depressive episode course current use medically accept contraception case female patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Borderline Personality Disorder</keyword>
	<keyword>ziprasidone</keyword>
</DOC>